Paclitaxel combination therapy in the treatment of metastatic breast cancer: a review.

摘要: Combinations of active antineoplastic agents have been the most effective treatment for metastatic breast cancer. Criteria an combination include use drugs with different mechanisms action, nonoverlapping toxic effects, and synergistic, or at least additive, antitumor activity. Paclitaxel (Taxol; Bristol-Myers Squibb Company, Princeton, NJ), its unique mechanism offers excellent opportunity development therapy against However, a number problems hindered rapid combinations. The obvious problem is lack defined optimal dose schedule administration. second has demonstration unexpected interactions between paclitaxel other component(s) combination, often resulting in unusual serious effects. This review will focus on phase I II trials established (except doxorubicin congeners, which covered elsewhere this issue) cancer: cisplatin, 5-fluorouracil without folinic acid, cyclophosphamide, radiation therapy, as well novel investigational strategies, edatrexate, monoclonal antibodies to oncogenes, growth factors, gene insertion multidrug resistance into blood stem cells. Combination exciting possibilities enhanced efficacy. given effects observed, only proven combinations should be used outside context clinical trial. Additionally, burden proof show that these increased activity, decreased toxicity, both compared single-agent paclitaxel.